Physician profile
Kenneth A Bauer
NPI 1558309849
$74,040.60
in general payments reported to CMS, 2019-2025
19 companies · $4,832 in 2025
The $4,832 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,240 · 2020: $20K · 2021: $5,233 · 2022: $4,653 · 2023: $23K · 2024: $7,567 · 2025: $4,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $1,916 · Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,162.67 |
| Travel and Lodging | $1,915.52 |
| Food and Beverage | $1,688.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32,669.07 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $15,019.77 | 2019-2022 | |
| Abbott Laboratories | $7,012.50 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $5,523.04 | 2020 | |
| Janssen Research & Development, LLC | $4,554.44 | 2019 | |
| Biomarin Pharmaceutical INC. | $2,200.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $2,120.00 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $1,560.00 | 2021-2024 | |
| Dova Pharmaceuticals | $1,392.22 | 2019 | |
| Cipla USA INC. | $427.00 | 2025 | |
| Zoll Medical Corporation | $406.67 | 2023 | |
| Alexion Pharmaceuticals, INC. | $362.91 | 2019-2022 | |
| Shire North American Group INC | $253.18 | 2019 | |
| Apellis Pharmaceuticals, INC. | $120.00 | 2023 | Empaveli |
| Genentech USA, INC. | $109.65 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $109.43 | 2022 | |
| Csl Behring | $92.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $92.53 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.